SFDA Kicks Off Drug Re-registration Examination And Approval
This article was originally published in PharmAsia News
Executive Summary
To ensure drug safety and eliminate low-quality and high-risk drugs, China's State FDA has officially started drug re-registration examinations and approvals. All provincial drug administrations will refer to the drug management methodology to conduct integrated checks on drug approval numbers, production techniques and prescription investigation results. Drugs will not be re-registered if their approval numbers are not genuine. In addition, SFDA demands that all provincial drug administrations set up records for drug re-registration to improve quality control and support routine supervision and on-site inspections. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.